Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART) - Scorecard - MDSpire

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

  • April 23, 2026

  • 4 min

Share

Clinical Scorecard: Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

At a Glance

CategoryDetail
ConditionProstate Cancer
Key MechanismsAdaptive stereotactic body radiation therapy (SBRT)
Target PopulationAdults with intermediate- and favorable high-risk adenocarcinoma of the prostate
Care SettingClinical trial setting

Key Highlights

  • Evaluates safety and effectiveness of adaptive SBRT
  • Treatment consists of 5 sessions over 2 to 3 weeks
  • Follow-up includes phone calls and clinic visits for monitoring

Guideline-Based Recommendations

Diagnosis

  • Histologically confirmed intermediate- and favorable high-risk prostate cancer
  • Pre-treatment diagnostic multiparametric MRI or PET/CT required

Management

  • Adaptive SBRT treatment every other day for a total of 5 fractions

Monitoring & Follow-up

  • Follow-up phone call at 6 weeks post-treatment
  • Clinic visits at 90 days, then every 3 months for the first year, and every 6 months thereafter

Risks

  • Exclusion of patients with CTCAE grade ≥ 3 GU or GI toxicity at baseline
  • Exclusion of patients with uncontrolled intercurrent illnesses

Patient & Prescribing Data

Men aged > 18 years with specific prostate cancer characteristics

Patients must meet strict inclusion criteria and have no prior pelvic radiation therapy

Clinical Best Practices

  • Ensure patients have full capacity to understand and sign informed consent
  • Utilize MRI for prostate volume assessment
  • Monitor testosterone levels for patients with prior ADT

References

Original Source(s)

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

  • April 23, 2026

Related Content

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

A spatial correlation-guided deep fusion framework for multimodal lung cancer classification using CT imaging

Editorial: Case reports in PET imaging 2024